Maze Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-5.4%projected annual EPS growth
Analyst Coverage
11analysts covering
FY Revenue (est.)
$20Mnext fiscal year
FY EPS (est.)
-$2.82next fiscal year
Monitoring Framework
Key Performance Indicators
MZE829 Clinical Trial Progress (Phase 2 HORIZON Trial) QuarterlyTarget: Pivotal trial initiation in moderate AMKD without diabetes
MZE782 Clinical Trial Progress (Phase 2 PKU and CKD Trials) QuarterlyTarget: Initiation of Phase 2 proof-of-concept trials
Cash Runway AnnuallyTarget: Fund operations into 2029
Watch Items
- Regulatory feedback on MZE829 pivotal trial designTrigger: Receipt of FDA/regulatory guidance in H2 2026 / H1 2027Action: Finalize protocol and initiate pivotal trial in the first half of 2027
- MZE782 Phase 2 PKU trial enrollment and initial dataTrigger: Topline data readout in 2027Action: Evaluate plasma phenylalanine reduction to confirm best-in-class profile
- MZE001 development milestones under Shionogi partnershipTrigger: Achievement of subsequent clinical or regulatory milestonesAction: Recognize milestone revenue and monitor Shionogi's global development progress
Research as of 20 Jun 2026